• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Researchers develop ‘nano cage’ to study cancer cell growth

March 29, 2017 By Sarah Faulkner

Researchers develop 'nano cage' to study cancer cell growth

Researchers at Kent State University and Kyoto University published work this week describing the genetic factors that help turn healthy cells into cancerous cells. The team’s work was published in Nature Nanotechnology. 

“Traditionally, DNA has a 2-strand shape — the double helix — and its purpose is to code the proteins that form life,” co-author Hanbin Mao said in prepared remarks. “But recently, people have discovered that some DNA has 4 strands, and we call this the G-quadruplex. This is associated with the inhibition of cancer cells.”

Although it’s helpful that G-quadruplex DNA inhibits cancer cells, some strands mutate and enable cancer cell profileration, according to the team. To better understand this phenomenon, the researchers had to learn why DNA turns into 4-stranded structures in the 1st place.

All DNA strands are generated by enzymes that operate like an assembly line. At some point, DNA either forms a double helix or a G-quadruplex. This formation process happens inside nanometer-sized spaces within the enzymes, Mao said.

Until now, researchers have been unable to mimic these spaces in a laboratory setting, which ultimately limited deeper study of the G-quadruplex formation process.

The team said they created a “nano cage” to study how DNA folded into different shapes inside.

“It’s easier for the DNA to fold inside the cage,” Mao said. “It folds to adapt to the small space, and here DNA naturally folds into the G-quadruplex.”

The process happens 2 to 3 orders of magnitude faster inside the cage than outside.

“With that observation, we may follow the fate of the cell to be cancerous or healthy,” he said. “So we can perhaps learn how to introduce molecules or chemicals to interfere with that process.”

Filed Under: Featured, Oncology, Research & Development Tagged With: Kent State University, Kyoto University

IN CASE YOU MISSED IT

  • Lyra Therapeutics appoints new chief medical officer
  • FDA lifts hold on Vertex’s insulin-producing cell therapy for diabetes
  • Retractable Technologies declares dividends
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • West Pharmaceutical Services debuts new needle syringe system

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS